Objectives:The objective of this study is to develop an experimental model of hyperlipidemia and insulin resistance (IR), markers of coronary heart disease (CHD) using high fat and high sugar (HFHS) diet and to evaluate the efficacy of the model using atorvastatin, a known antihyperlipidemic drug, pioglitazone, a known insulin sensitizer, and Tinospora cordifolia (Tc), an antidiabetic plant.Materials and Methods:Following Institutional Animal Ethics Committee permission, the study was conducted in male Wistar rats (200-270 g). The model was developed using a high fat (vanaspati ghee: coconut oil, 3:1) oral diet along with 25% fructose (high sugar) added in drinking water over a period of 6 weeks. Atorvastatin (2.1 mg/kg/day), pioglitazone (2.7 mg/kg/day) and Tc (200 mg/kg/day) were administered 3 weeks after initiation of HFHS diet and continued for another 3 weeks. Parameters assessed were weight, lipid profile, fasting blood glucose, insulin, and gastric emptying. Serum malondialdehyde (MDA) and catalase were assessed as markers of oxidative stress.Results:Administration of HFHS diet demonstrated a significant increase in blood glucose, insulin, total and low density lipoprotein cholesterol and triglycerides with a decrease in high density lipoprotein cholesterol. Treatment with test drugs decreased blood sugar, insulin, lipid parameters, increased gastric emptying rate, decreased MDA levels, and catalase activity when compared to HFHS diet group, confirming the efficacy of the model. Atherogenic index of all the test drugs (0.48, 0.57, and 0.53) was significantly lower as compared to HFHS diet group (1.107).Conclusion:This study confirms the development of a diet based cost-effective and time efficient experimental model, which can be used to study two important markers of cardiovascular disease that is, hyperlipidemia and IR and to explore the efficacy of new molecules in CHD.

Plumbagin is a naphthoquinone found in the roots of Plumbago zeylanica. Here, we report an investigation to evaluate its antiobesity activity. The preliminary binding affinity of plumbagin to human pancreatic lipase (PL) was determined using molecular docking simulation. The in vitro PL inhibitory potential and the kinetics of inhibition were studied to validate and confirm the results obtained from molecular docking. The IC for PL was found to be 82.08 ± 9.47 μM, and the kinetics of inhibition was found to be of the mixed type. Further, the in vivo evaluation revealed that rats treated with plumbagin 1 mg/kg showed significant decrease in serum triglycerides (TG) and area under the curve of serum TG when compared with vehicle-treated rats. It was also seen that plumbagin possessed significant antiadipogenic effect as demonstrated by reduced oil red O staining and decreased TG contents. Thus, we conclude that plumbagin is a promising molecule to combat obesity and further optimization of plumbagin to yield plumbagin analogues will result in its improved activity profile.

Introduction The authors had previously conducted an in-vitro study to observe the effect of homeopathic medicines on melanogenesis, demonstrating anti-vitiligo potential by increasing the melanin content in murine B16F10 melanoma cells. A similar experiment was performed using further homeopathic preparations sourced from kojic acid (KA), hydrogen peroxide (H2O2; HP), 6-biopterin (BP), and [Nle4, D-Phe7]-α-melanocyte-stimulating hormone (NLE), some of which are known to induce vitiligo or melano-destruction at physiological dose. Materials and Methods The homeopathic preparations of BP, KA, NLE, and HP were used in 30c potency. Alcohol and potentized alcohol were used as vehicle controls. Prior to starting the main experiment, the viability of B16F10 melanoma cells after treatment with study preparations was assayed. Melanin content (at 48 h and 96 h) and tyrosinase activity in melanocytes were determined. Results At the end of 48 hours, NLE and HP in 30c potency had a significantly greater melanin content (p = 0.015 and p = 0.039, respectively) compared with controls; BP and KA in 30c potency had no significant effects. No significant changes were seen at the end of 96 hours. KA, NLE, HP, and vehicle controls showed an inhibition of tyrosinase activity. Conclusion The study demonstrated melanogenic effects of two homeopathic preparations. Further research to evaluate the therapeutic efficacy of these medicines is warranted.

Background Osteoporosis is a public health problem in the elderly wherein a decrease in bone mass and mineral density increases the at risk of fractures. Panchatikta Ghrita (PG) is a classical Ayurvedic formulation that may help slow bone degeneration. Objective This experimental study was conducted to assess the efficacy of Panchatikta ghrita (PG) in protecting against postmenopausal osteoporosis in ovariectomized rats. Materials and methods The experiment was initiated after Institutional Animal Ethics Committee approval. 96 female Sprague Dawley rats were divided into 8 groups viz. sham control (NC), diseased control (DC), vehicle control (VC), 3 test drug (PG) groups (PG1, PG2 & PG3 - 0.9, 1.8 and 2.7gm/kg body weight respectively) and 2 standard control (SC) groups - SC1 received 17α-ethinylestradiol 1μg/kg/day while SC2 received alendronate (7mg/kg/week). Study medications were administereddaily for four months. Bone specific biomarkers viz. osteocalcin and TRAP-5b were estimated at baseline and end of study. Animals were sacrificed on day 121 and their femurs and tibiae were harvested for histomorphometric analysisand bone microarchitectural studies. Results Serum osteocalcin and TRAP-5b showed significant increase (p < 0.001) in levels in DC group as compared to sham controls. All 3 doses of PG decreased bone specific biomarker levels with maximal effect seen with highest dose of PG similar to that seen with standard drugs. PG also significantly improved bone micro architectural parameters like bone mineral density and mineral content at higher dose levels. Decrease in osteoclasts and significant dose dependent increase in bone hardness and elasticity was seen with PG which was comparable to standard drugs. Conclusion PG increased bone mineral density and content, decreased turnover of bone specific biomarkers and osteoclast formation, indicating its protective effect against experimentally induced postmenopausal osteoporosis.

<p>Yograj Guggul (<em>YG</em>) is a poly-herbal formulation extensively used by Ayurvedic practitioners to treat inflammatory conditions. However there are no reports evaluating its effect on the various enzymes involved in the inflammatory pathway. Hence the present was carried out to evaluate the anti-inflammatory effect of <em>YG</em>, on inhibition of Cyclooxygenase (COX) - 1 &amp; 2 and 5-Lipoxygenase (LOX) enzymes <em>in vitro</em>. Three concentrations (25, 50 and 100µg/ml) of the aqueous extract of <em>YG </em>were studied on the inhibition of COX 1 &amp; 2 and 5-LOX enzymes by Enzyme Immuno Assay (EIA). Aspirin was used as a positive control at concentration corresponding to its anti-inflammatory human dose (100µg/ml).<em>YG</em> exhibited maximum inhibition of both COX-1 &amp;COX-2 enzymes at 100µg/ml that was comparable to aspirin. Interestingly, <em>YG </em>showed a dose dependent increase in percentage inhibition of 5-LOX enzyme with maximum effect at 100µg/ml which was significantly higher than that exhibited by aspirin. <em>YG</em> inhibits both COX enzymes indicating its potential as an anti-inflammatory agent. The 5-LOX inhibitory activity exhibited by <em>YG</em> provides a lead to explore its role further as a dual inhibitor of COX/5-LOX pathways and also to investigate its role to treat inflammatory respiratory disorders.</p>